Summary
This Form 8-K from Gilead Sciences, Inc. (GILD) details the outcomes of its 2017 Annual Meeting of Stockholders held on May 10, 2017. The primary focus for investors revolves around the approval of the restated Gilead Sciences, Inc. 2004 Equity Incentive Plan, which was subsequently approved by stockholders. This plan is crucial for executive and employee compensation, impacting future stock-based awards and dilution. Furthermore, the report confirms the election of nine directors to the Board and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017. Stockholders also provided advisory approval for the compensation of named executive officers and voted on the frequency of future advisory votes on executive compensation, with a preference for annual votes.
Key Highlights
- 1Gilead Sciences' stockholders approved the restatement of the 2004 Equity Incentive Plan on May 10, 2017, subject to prior Board approval.
- 2Nine directors were elected to serve on the Board of Directors for the ensuing year.
- 3Ernst & Young LLP was ratified as Gilead's independent registered public accounting firm for the fiscal year ending December 31, 2017.
- 4Stockholders provided advisory approval for the compensation of the company's named executive officers.
- 5A majority of stockholders voted in favor of holding an advisory vote on executive compensation annually.
- 6Two stockholder proposals, one regarding stockholder action by written consent and another for an independent Board Chairman, were not approved.